Laser photocoagulation vs. intravitreal (IVT) aflibercept for ROP
Reviewed by Fiona Rowe

The efficacy, recurrence rate and requirement for additional treatment were compared between laser photocoagulation and IVT of 1mg/0.025ml aflibercept in the treatment of retinopathy of prematurity (ROP). The study included 27 babies (51 eyes) who completed a follow-up period after treatment. The laser group included 27 eyes of 15 babies; 252 eyes at stage 3 and two eyes at stage 2. The IVT group included 24 eyes of 12 babies; 14 eyes at stage 3 and 10 eyes with aggressive post ROP (APROP). There were no treatment related complications for either group. Regression rates after treatment were 92.6% and 100% respectively for laser and IVT. Recurrence rate was 30% in the laser group and 25% of all eyes treated for recurrence. Ten patients with IVT required laser photocoagulation treatment during follow-up. The authors conclude that IVT with aflibercept is an effective treatment. However, it needs more additional treatment during follow-up than the laser photocoagulation group.

Comparison of the efficacy between intravitreal aflibercept and laser photocoagulation in the treatment of ROP.
Ekinci DY, Celik K.
JOURNAL OF PEDIATRIC OPHTHALMOLOGY AND STRABISMUS
2020;57:54-60.